These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
153 related items for PubMed ID: 10485504
1. Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. Dobrilla G, Piazzi L, Fiocca R. Clin Ther; 1999 Aug; 21(8):1321-32. PubMed ID: 10485504 [Abstract] [Full Text] [Related]
2. [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial]. Petite JP, Slama JL, Licht H, Lemerez M, Coste T, Andrieu J, Grimaud JC, Julien H, Dupuis J, Sallerin V. Gastroenterol Clin Biol; 1993 Aug; 17(5):334-40. PubMed ID: 8349067 [Abstract] [Full Text] [Related]
3. A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. Avner DL, Dorsch ER, Jennings DE, Greski-Rose PA. Aliment Pharmacol Ther; 1995 Oct; 9(5):521-8. PubMed ID: 8580272 [Abstract] [Full Text] [Related]
4. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. Russo A, Dattilo M. Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183 [Abstract] [Full Text] [Related]
5. Continuous maintenance with low-dose lansoprazole versus Helicobacter pylori eradication in the prevention of duodenal ulcer recurrence. Parente F, Bargiggia S, Bollani S, Colombo E, Bianchi Porro G. Hepatogastroenterology; 1998 Aug; 45(22):990-3. PubMed ID: 9755995 [Abstract] [Full Text] [Related]
6. Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. Bardhan KD, Crowe J, Thompson RP, Trewby PN, Keeling PN, Weir D, Crouch SL. Aliment Pharmacol Ther; 1999 Jun; 13(6):827-32. PubMed ID: 10383514 [Abstract] [Full Text] [Related]
10. Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. Luzza F, Giglio A, Ciliberto E, Belmonte A, Cavaliere C, Saccà N, Frandina C, Fiocca R, Trimboli V, Pallone F. Clin Ther; 2001 May; 23(5):761-70. PubMed ID: 11394734 [Abstract] [Full Text] [Related]
11. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Hawkey CJ, Long RG, Bardhan KD, Wormsley KG, Cochran KM, Christian J, Moules IK. Gut; 1993 Oct; 34(10):1458-62. PubMed ID: 8244121 [Abstract] [Full Text] [Related]
12. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Schwartz H, Krause R, Sahba B, Haber M, Weissfeld A, Rose P, Siepman N, Freston J. Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452 [Abstract] [Full Text] [Related]
13. Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. Hotz J, Kleinert R, Grymbowski T, Hennig U, Schwarz JA. Aliment Pharmacol Ther; 1992 Feb; 6(1):87-95. PubMed ID: 1543819 [Abstract] [Full Text] [Related]